Asymptomatic hyperuricemia: To treat or not to treat

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 8, 2002, Pages 594-608

  Dincer, H Erhan ^a   Dincer, Ayse P ^a   Levinson, Dennis J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; AMPICILLIN; AZATHIOPRINE; CALCITONIN; CORTICOTROPIN; DIDANOSINE; ESTROGEN; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; MECLOFENAMIC ACID; MERCAPTOPURINE; OXIPURINOL; PHENYLBUTAZONE; PROBENECID; SALICYLIC ACID; SULFINPYRAZONE; URIC ACID; URICOSURIC AGENT;

ANAMNESIS; CARDIOVASCULAR DISEASE; DIARRHEA; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSLIPIDEMIA; EOSINOPHILIA; FAMILY HISTORY; FEVER; GOUT; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LEUKOCYTOSIS; PATHOGENESIS; PREECLAMPSIA; RASH; REVIEW; RISK FACTOR; SKIN MANIFESTATION; SYMPTOMATOLOGY; SYNDROME X; URIC ACID STONE;

EID: 0036685042     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.8.594     Document Type: Review

References (56)

1. Clinical gout and pathogenesis of hyperuricemia
2. Sex differences in uric acid metabolism in adults: Evidence for a lack of influence of estradiol-17 on the renal handling of urate metabolism
3. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis
4. Indirect coupling between sodium and urate transport in the proximal tubule
5. Urate excretion in normal and gouty men
6. Asymptomatic hyperuricemia: Risks and consequences in the Normative Aging Study
7. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program
8. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study
9. Uric acid nephrolithiasis in gout. Predisposing factors
10. Renal outcomes of gout and hyperuricemia
11. Randomized trial of allopurinol in the prevention of calcium oxalate calculi
12. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease
13. Tubular function impairment in patients with asymptomatic hyperuricemia
14. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study
15. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey
16. Serum urate and the risk of major coronary heart disease events
17. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study
18. Hyperuricemia and risk of cardiovascular disease and overall death: A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden
19. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study
20. Release of platelet constituents by monosodium urate crystals
21. Blood coagulation and platelet economy in subjects with primary gout
22. Hyperuricemia in coronary, cerebral and peripheral arterial disease: An explanation
23. Hyperlipoproteinemia in primary gout and asymptomatic hyperuricemia
24. Lipoproteins in patients with isolated hyperuricemia
25. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: The CARDIA Study
26. Metabolic syndrome X: A review
27. The kidney: An unwilling accomplice in syndrome X
28. Main causes of hyperuricemia in diabetes mellitus
29. Rheumatic manifestations in human immunodeficiency virus positive and negative individuals: A study of 2 populations with similar risk factors
30. Acquired immunodeficiency syndrome-associated arthrities
31. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine
32. Overview of phase I trials of 2′,3′-dideoxyinosine (ddl) conducted on adult patients
33. Uric acid and didanosine compliance in AIDS clinical trials: An analysis of AIDS clinical trials group protocols 116A and 116B/117
34. Hyperuricemia and gout
35. Hyperuricemia and gout
36. Hyperuricemia and progression of HIV disease
37. Hyperuricemia in pre-eclampsia. A reappraisal
38. The clinical utility of serum uric acid measurements in hypertensive disease of pregnancy
39. Gout
40. Hyperuricemic acute renal failure
41. The economic implications of the prevention of gouty arthritis
42. A survey of current prescribing practices in gouty arthritis and asymptomatic hyperuricemia in Sao Paulo, Brazil
43. Ethanol-induced hyperuricemia: Evidence for increased urate production by activation of adenine turnover
44. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality
45. The management of gout
46. Allergic reaction to allopurinol with cross-reactivity to oxypurinol
47. Allopurinol in renal failure and tumor lysis syndrome
48. Glycogen storage diseases
49. Renal complications in glycogen storage diseases type I
50. Molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man
51. Inherited superactivity of phosphoribosyl phosphate synthetase: Association of uric acid overproduction and sensorineural deafness
52. Hypoxanthine-guanine phosphoribosyl transferase variants: Correlation of clinical phenotype with enzyme activity
53. A review of the molecular basis of hypoxanthine guanine phosphoribosyl transferase (HGPRT) deficiency
54. Failure to thrive, hyperuricemia and renal insufficiency in early infancy secondary to partial hypoxanthine guanine phosphoribosyl transferase deficiency
55. A missense mutation in the hypoxanthine phosphoribosyltransferase gene in a pediatric patient with hyperuricemia
56. Accelerated transcription of PRS 1 in X-linked overactivity of normal human phosphoribosyl pyrophosphate synthetase